Last reviewed · How we verify
AVX901
At a glance
| Generic name | AVX901 |
|---|---|
| Also known as | VRP-HER2 ECDTM |
| Sponsor | H. Kim Lyerly |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (PHASE2)
- A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AVX901 CI brief — competitive landscape report
- AVX901 updates RSS · CI watch RSS
- H. Kim Lyerly portfolio CI